Tech Company Financing Transactions
Cour Pharmaceuticals Funding Round
On 9/7/2022, Cour Pharmaceuticals raised $30 million in funding from Alpha Wave Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/7/2022
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Alpha Wave Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand its CNP platform technology and advance its two human proof-of-concept studies in Primary Biliary Cholangitis and Peanut allergy, as well as development programs in Myasthenia Gravis and Type 1 Diabetes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8025 Lamon Ave.
Skokie, IL 60077
USA
Skokie, IL 60077
USA
Phone
Undisclosed
Website
Email Address
Overview
COUR Pharmaceuticals is developing ?rst-in-class therapies designed to reprogram the immune system to achieve antigen-speci?c tolerance for immune-mediated disease. COUR's platform of immune-modifying nanoparticles aims to treat the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Puisis
Chief Financial Officer
Brian Bock
VP - Finance
Nick Bortolotti
VP - General Counsel
Tracy Weiner
VP - Product Management
Michael Boyne
Browse more venture capital transactions:
Prev: 9/7/2022: QA Wolf venture capital transaction
Next: 9/7/2022: Circuit venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs